Giuseppe Lamberti

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Biagio Ricciuti, Xinan Wang, Joao V. Alessi et al. · JAMA Oncology · 2022 · 356 citations · Full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi et al. · Journal of Thoracic Oncology · 2021 · 346 citations · Full text

Tumor Biology, Programmed Death-, Medicine +10

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Gonzalo Recondo, Magda Bahcall, Liam F. Spurr et al. · Clinical Cancer Research · 2020 · 210 citations

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Hamzah Abu‐Sbeih, David M. Faleck, Biagio Ricciuti et al. · Journal of Clinical Oncology · 2019 · 188 citations · Full text

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti et al. · Cancer Discovery · 2023 · 166 citations · Full text